Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied
Johnson & Johnson reports Q3 2024 results
• 2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* • 2024 Third-Quarter Earnings per share (EPS) of $1.11 dec
What you need to know about Johnson & Johnson’s 2024 third quarter earnings
Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.
What is a rheumatic disease?
A rheumatic disease typically affects joints and connective tissues. Learn more about the different types, symptoms and risk factors.
5 things we now know about Sjögren’s Disease
Here are five things we now know about Sjögren’s disease.
Johnson & Johnson MedTech Launches VOLT™ Plating System
Next-Generation Plating System combines flexibility and stability for advanced fracture care1-4* across orthopaedic procedures5,6
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy.1 Data showed that
Johnson & Johnson Completes Acquisition of V-Wave
Adds V-Wave’s Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
Lynne Maquat, Ph.D., and Alexander Varshavsky, Ph.D., to receive 2024 Dr. Paul Janssen Award for their fundamental discoveries about regulated degradation of RNA and proteins.
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
New Brunswick, N.J., October 4th, 2024 – Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Bost
Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue
No safety issues identified to date
Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session
· Oral session, featuring nipocalimab results in adolescents living with gMG represents first FcRn blocker data to be presented focusing on this population with high unmet medical need · Oral and post
Johnson & Johnson Announces Collaborative Effort with USAID to Strengthen the Health Workforce Across Latin America and the Caribbean
Memorandum of Understanding will support the Americas Health Corps in its goal to train 500,000 health workers to help build strong and resilient health systems and bring more communities closer to care
Johnson & Johnson files for U.S. FDA approval of DARZALEX
Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility New indication would be the fi
What’s the difference between a heart attack and cardiac arrest?
For National Sudden Cardiac Arrest Awareness Month, learn more about the differences between a heart attack and a cardiac arrest.
Johnson & Johnson to invest more than $2 billion in new, advanced technology manufacturing facility in North Carolina to support robust portfolio growth
OCTOBER 1, 2024 – Johnson & Johnson (NYSE: JNJ) today announced an investment of more than $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. The new fa
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3†. 93% of patients become free from glasses at all distances. #4‡ TECNIS Odyssey I
Novel combination of TALVEY
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies
What you need to know about Johnson & Johnson’s 2023 transparency report
The annual report has just been released—here are key takeaways that showcase the company's commitment to creating a more sustainable, equitable and innovative healthcare system.
